183 related articles for article (PubMed ID: 33094598)
1. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.
Vandepapelière J; Siplet J; Libbrecht L; Dano H; Baurain JF; Moreels T
Acta Gastroenterol Belg; 2020; 83(3):482-484. PubMed ID: 33094598
[TBL] [Abstract][Full Text] [Related]
2. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
Rao BB; Robertson S; Philpott J
Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
[No Abstract] [Full Text] [Related]
4. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma.
Kim H; Ha SY; Kim J; Kang M; Lee J
Curr Oncol; 2020 Aug; 27(4):e436-e439. PubMed ID: 32905211
[TBL] [Abstract][Full Text] [Related]
5. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy.
Gaffuri P; Espeli V; Fulciniti F; Paone G; Bergmann M
Pathologica; 2019 Sep; 111(3):92-97. PubMed ID: 31748755
[TBL] [Abstract][Full Text] [Related]
6. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
7. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
[TBL] [Abstract][Full Text] [Related]
8. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
9. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
10. Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab - Differences and Similarities in Comparison to "endogenous" autoimmune Type A Gastritis and a review of literature.
Ecker ME; Weckauf H; Tebbe S; Schuppert F
Z Gastroenterol; 2023 Oct; 61(10):1385-1393. PubMed ID: 36963423
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C
N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430
[TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-associated erythema nodosum in the treatment of metastatic melanoma.
O'Connor C; Finnegan P; Power DG; Bennett M; Bourke JF
Immunotherapy; 2022 Sep; 14(13):1021-1026. PubMed ID: 35892257
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report.
Jabkowski J; Loidl A; Auinger B; Kehrer H; Sepp N; Pichler R
Front Immunol; 2021; 12():606056. PubMed ID: 34220792
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
19. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
Sullivan RJ; Flaherty KT
Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]